Efficacy and safety of autologous whole blood clot in diabetic foot ulcers: a randomised controlled trial
Wirksamkeit und Sicherheit eines autologen Vollblutgerinnsels bei diabetischen Fußulzera: randomisierte kontrollierte Studie
Journal of Wound Care · 02.09.2024 · 33 (9) · 688-700
DOI: 10.12968/jowc.2024.0195 ↗Auf einen Blick
Bei 119 Patient:innen mit schwer heilenden diabetischen Fußulzera war autologes Vollblutgerinnsel plus Standardversorgung mit höheren Heilungsraten verbunden als Standardversorgung allein.
Fragestellung
Wirksamkeit und Sicherheit eines autologen Vollblutgerinnsels (AWBC) zusätzlich zur Standardversorgung im Vergleich zur Standardversorgung allein bei schwer heilenden diabetischen Fußulzera.
Methode
Multizentrische, prospektive, verblindete Beurteilung, randomisierte kontrollierte Studie an 16 Zentren in den USA, Südafrika und der Türkei.
Ergebnisse
119 Patient:innen. Komplettverschluss nach 12 Wochen: ITT 41 % vs. 15 %; p=0,002. PP 51 % vs. 18 %; p=0,0075. Kürzere mittlere Heilungszeit und höhere Dauerhaftigkeit des Wundverschlusses; ähnliche AE-Inzidenz, keine device-related AEs.
Schlussfolgerung der Autor:innen
Das AWBC-System bot in dieser Studie einen vielversprechenden neuen Ansatz zur Behandlung schwer heilender diabetischer Fußulzera und zeigte bessere Heilungsergebnisse als Standardversorgung allein.
Kernaussagen
- Komplettverschluss nach 12 Wochen häufiger unter AWBC als unter Standardversorgung
- ITT: 41 % vs. 15 %; PP: 51 % vs. 18 %
- Sicherheitsanalyse: ähnliche AE-Inzidenz, keine device-related AEs
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Wound Care, erschienen am 02.09.2024. Verfasst von Robert Snyder und 16 weiteren Autor:innen. Beteiligte Einrichtung: Barry University Clinical Research, North Miami Beach, FL, US. Hauptthemen laut MEDLINE: Diabetic Foot, Wound Healing. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Objective
Diabetic foot ulcers (DFUs) present a significant global health challenge, resulting in high morbidity and economic costs. Current available treatments often fail to achieve satisfactory healing rates, highlighting the need for novel therapies. This study evaluated the safety and efficacy of a novel autologous whole blood clot (AWBC)—a blood-based, biodegradable provisional matrix—in conjunction with standard of care (SoC) when compared to SoC alone in the treatment of hard-to-heal DFUs.
Method
A multicentre, prospective, blinded assessor, randomised controlled trial was conducted at 16 sites across the US, South Africa and Turkey. A cohort of patients with hard-to-heal DFUs was enrolled and randomised to either the AWBC group or the control group. The primary endpoint was complete wound closure at 12 weeks, while secondary endpoints included time to heal and percentage area reduction (PAR) at four and eight weeks. Data were analysed using both intention-to-treat (ITT) and per-protocol (PP) populations.
Results
The cohort included 119 patients. AWBC treatment resulted in a significantly higher healing rate compared to the control in both ITT (41% versus 15%, respectively; p=0.002) and PP populations (51% versus 18%, respectively; p=0.0075). AWBC treatment also resulted in a shorter mean time to heal and higher durability of wound closure. Safety analysis showed a similar incidence of adverse events (AEs) between groups, with no device-related AEs.
Conclusion
The AWBC system, by modulating the wound microenvironment and providing a functional extracellular matrix, offered a promising new approach to treating hard-to-heal DFUs, demonstrating superior healing outcomes compared to SoC alone in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Barry University Clinical Research, North Miami Beach, FL, US.
- Olive View UCLA Education & Research Institute, Sylmar, CA, US.
- VA Greater Los Angeles Healthcare System, Los Angeles, CA, US.
- Wahab Consulting and Research LLC, Las Vegas, NV, US.
- Institute for Advanced Wound Care at Baptist Medical Center South, Montgomery, AL, US.
- Wound Care South Africa, Germiston, South Africa.
Zitieren
APA
Snyder, R., Nouvong, A., Ulloa, J., Wahab, N., Treadwell, T., Bruwer, F., Naude, L., McGuire, J., Reyzelman, A. M., Graham, T., AWBC Research Team:, Lessing, R., Lullove, E., Ozker, E., Pham, H. T., Pasternac, M., & Cohen, S. (2024). Efficacy and safety of autologous whole blood clot in diabetic foot ulcers: a randomised controlled trial. Journal of Wound Care, 33(9), 688-700. https://doi.org/10.12968/jowc.2024.0195
Vancouver
Snyder R, Nouvong A, Ulloa J, Wahab N, Treadwell T, Bruwer F, et al. Efficacy and safety of autologous whole blood clot in diabetic foot ulcers: a randomised controlled trial. Journal of Wound Care. 2024;33(9):688-700. doi:10.12968/jowc.2024.0195
BibTeX
@article{Snyder2024,
author = {Snyder, Robert and Nouvong, Aksone and Ulloa, Jesus and Wahab, Naz and Treadwell, Terry and Bruwer, Febe and Naude, Liezl and McGuire, James and Reyzelman, Alexander M and Graham, Timothy and AWBC Research Team:, AWBC Research Team: and Lessing, Rene and Lullove, Eric and Ozker, Emre and Pham, Hau T and Pasternac, Michael and Cohen, Shira},
title = {Efficacy and safety of autologous whole blood clot in diabetic foot ulcers: a randomised controlled trial},
journal = {Journal of Wound Care},
year = {2024},
volume = {33},
number = {9},
pages = {688--700},
doi = {10.12968/jowc.2024.0195}
}
EUVIMED